L-arginine and Brown Adipose Tissue

NCT ID: NCT02291458

Last Updated: 2014-11-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-30
• Study Completion Date: 2015-12-31

Brief Summary

The South Asian population is facing an epidemic of type 2 diabetes, of which the underlying cause is still unknown. It is currently hypothesized that an ethnic susceptibility towards a disturbed energy metabolism may underlie this disadvantageous metabolic phenotype. In line with this, the investigators recently discovered that Dutch South Asian subjects have 32% lower resting energy expenditure (REE) and 34% lower energy-combusting brown adipose tissue (BAT) compared to matched white Caucasians. Nitric oxide (NO) was recently shown to be crucial for BAT development and, interestingly, South Asians have diminished NO bioavailability. Thus, the disadvantageous metabolic phenotype in South Asians may be caused by diminished NO bioavailability resulting in lower BAT volume. Therefore, the investigators hypothesize that increasing NO generation in the body by administration of L-arginine, the precursor of NO, will improve their metabolic phenotype by increasing BAT volume, thereby increasing REE and clearance of triglycerides and glucose by BAT. To investigate this, the investigators will perform a randomized placebo-controlled multicenter cross-over study in moderately obese Dutch South Asians and matched white Caucasians. Subjects will receive L-arginine (9 gram/day) or placebo for 6 weeks, followed by a wash-out period of 4 weeks and then again 6 weeks of one of either treatments. At the end of both treatment periods, a cold-induced PET-CT scan will be performed. Furthermore, muscle and fat biopsies will be obtained and thermoregulation will be assessed.

Detailed Description

Rationale: The South Asian population originally descends from the Indian subcontinent and represents approximately 20% of the total world population. This population is facing an epidemic of type 2 diabetes, of which the underlying cause is still unknown. A high prevalence of a disadvantageous metabolic phenotype, consisting of obesity, insulin resistance and dyslipidemia, may at least in part contribute to this excess risk. It is currently hypothesized that an ethnic susceptibility towards a disturbed energy metabolism may underlie this disadvantageous metabolic phenotype. In line with this, the investigators recently discovered that Dutch South Asian subjects have 32% lower resting energy expenditure (REE) and 34% lower energy-combusting brown adipose tissue (BAT) compared to matched white Caucasians. Nitric oxide (NO) was recently shown to be crucial for BAT development and, interestingly, South Asians have diminished NO bioavailability. Thus, the disadvantageous metabolic phenotype in South Asians may be caused by diminished NO bioavailability resulting in lower BAT volume. Therefore, the investigators hypothesize that increasing NO generation in the body by administration of L-arginine, the precursor of NO, will improve their metabolic phenotype by increasing BAT volume, thereby increasing REE and clearance of triglycerides and glucose by BAT.

Objectives: The primary objectives are: 1) to determine the effect of L-arginine on glucose uptake by brown adipose tissue and to assess whether the effect differs between South Asian and white Caucasian subjects; 2) to determine the effect of L-arginine on whole body energy expenditure and to assess whether the effect differs between South Asian and white Caucasian subjects; 3) to determine the effect of L-arginine on fat mass and to assess whether the effect differs between South Asian and white Caucasian subjects.

Study design: A randomized placebo-controlled multicenter cross-over study will be performed in moderately obese Dutch South Asians and matched white Caucasians. Subjects will receive L-arginine (9 gram/day) or placebo for 6 weeks, followed by a wash-out period of 4 weeks and then again 6 weeks of one of either treatments. At the end of both treatment periods, a cold-induced PET-CT scan will be performed. Furthermore, muscle and fat biopsies will be obtained, thermoregulation will be assessed, an oral glucose tolerance will be performed and the investigators will assess NO-dependent and independent vasodilation by means of iontophoresis.

Study population: Mildly obese (BMI 25-30 kg/m2) pre-diabetic male volunteers of South Asian and white Caucasian descent aged between 35-50 years.

Intervention: The intervention will consist of administration of 9 grams of L-arginine per day in three gifts (3dd 3 gram).

Conditions

Adipose Tissue, Brown; Glucose Intolerance; Nitric Oxide

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

L-arginine

Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.

Group Type: EXPERIMENTAL

L-arginine

Intervention Type: DRUG

9 gram L-arginine / day for 6 weeks

Placebo

Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

9 gram placebo / day for 6 weeks

Interventions

L-arginine

9 gram L-arginine / day for 6 weeks

Intervention Type: DRUG

Placebo

9 gram placebo / day for 6 weeks

Intervention Type: DRUG

Other Intervention Names

Argimax

Eligibility Criteria

Inclusion Criteria

• Caucasian or South Asian ethnicity
• Age: 35-50 years
• Gender: male
• BMI: 25-30 kg/m2
• Plasma glucose levels 2 h after OGTT between 7.8 and 11 mM (e.g. impaired glucose tolerance) or Fasting plasma glucose levels > 5.5 mM
• Good general health

Exclusion Criteria

• Type 2 diabetes (determined on basis of oral glucose tolerance test (OGTT))
• BMI > 30 kg/m2
• Plasma glucose levels 2 h after OGTT < 7.8 mM
• Plasma L-arginine levels < 41 or > 114 uM
• Use of beta-blockers (these inhibit BAT activity) < 1 month before start of study or during study
• Systolic blood pressure < 90 mmHg
• Haematocrit < 0.41 or > 0.51 l/l
• Haemoglobin < 8.5 or > 11.0
• Creatinine (enzymatic method) < 45 or > 100 μmol/L
• ASAT > 45 U/L
• ALAT > 50 U/L
• Alkaline phosphatase > 125 U/L
• Gamma GT > 45 U/L
• Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study
• Abuse of drugs and/or alcohol
• Hyperthyroidism or hypothyroidism
• Participation in earlier research or medical examinations that included PET-CT scanning
• Psychologically unstable subjects (as judged by the treating medical specialist)
• Subjects with mental retardation (as judged by the treating medical specialist)
• Subjects with severe behaviour disorders (as judged by the treating medical specialist)

• Minimum Eligible Age: 35 Months
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Leiden University Medical Center

OTHER

Sponsor Role: collaborator

Maastricht University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Maastricht University Medical Center +

Maastricht, Limburg, Netherlands

Site Status: RECRUITING

Countries

Netherlands

Facility Contacts

Mariette Boon, PhD

Role: primary

m.boon@maastrichtuniversity.nl

+31648126425

Wouter van Marken Lichtenbelt, PhD

Role: backup

markenlichtenbelt@maastrichtuniversity.nl

Tel: +31 43 388 1629

References

Janssen LGM, Van Dam AD, Hanssen MJW, Kooijman S, Nahon KJ, Reinders H, Jazet IM, Van Marken Lichtenbelt WD, Rensen PCN, Appelman-Dijkstra NM, Boon MR. Higher Plasma Sclerostin and Lower Wnt Signaling Gene Expression in White Adipose Tissue of Prediabetic South Asian Men Compared with White Caucasian Men. Diabetes Metab J. 2020 Apr;44(2):326-335. doi: 10.4093/dmj.2019.0031. Epub 2019 Oct 31.

Reference Type: DERIVED

PMID: 31701693 (View on PubMed)

Boon MR, Hanssen MJW, Brans B, Hulsman CJM, Hoeks J, Nahon KJ, Bakker C, van Klinken JB, Havekes B, Schaart G, Jazet IM, Rensen PCN, van Marken Lichtenbelt WD. Effect of L-arginine on energy metabolism, skeletal muscle and brown adipose tissue in South Asian and Europid prediabetic men: a randomised double-blinded crossover study. Diabetologia. 2019 Jan;62(1):112-122. doi: 10.1007/s00125-018-4752-6. Epub 2018 Oct 30.

Reference Type: DERIVED

PMID: 30377712 (View on PubMed)

Nahon KJ, Kantae V, den Haan R, Hanssen MJW, Harms AC, van der Stelt M, Hankemeier T, Jazet IM, van Marken Lichtenbelt WD, Rensen PCN, Boon MR. Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight. Obesity (Silver Spring). 2018 Aug;26(8):1332-1337. doi: 10.1002/oby.22245. Epub 2018 Aug 1.

Reference Type: DERIVED

PMID: 30070030 (View on PubMed)

Other Identifiers

NL2014-001733-86

Identifier Type: -

Identifier Source: org_study_id